Protagonist Therapeutics PTGX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$114.71M-304% | -$130.15M-147% | $45.91M— | $52.04M— | $56.19M— | ||
| $1.45M+74.7% | $1.28M+55.0% | $1.02M+6.9% | $892K-7.9% | $829K-14.1% | ||
| $46.69M+11.2% | $45.97M+22.4% | $44.37M+26.5% | $43.97M+38.9% | $42M+35.2% | ||
| —— | —— | —— | —— | —— | ||
| $1.26M-24.0% | $1.59M+17.3% | $1.76M+65.0% | $2.44M+253% | $1.66M+97.1% | ||
| —— | —— | —— | —— | -$399.96M-830% | ||
| $34.8M+15.6% | $22.86M-11.6% | $24.06M+7.6% | $30.45M-33.2% | $30.1M-80.1% | ||
| —— | —— | —— | -$187.04M— | -$32.92M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Protagonist Therapeutics generate?
- Protagonist Therapeutics (PTGX) generated $317.6M in operating cash flow over the trailing twelve months.
- What is Protagonist Therapeutics's free cash flow?
- After $1.3M of capital expenditures, Protagonist Therapeutics's free cash flow was $316.6M over the trailing twelve months, up 364.9% year over year.
- Where does Protagonist Therapeutics's cash flow data come from?
- Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
